Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

108 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Plasma levels of matrix metalloproteinase-2, -3, -10, and tissue inhibitor of metalloproteinase-1 are associated with vascular complications in patients with type 1 diabetes: the EURODIAB Prospective Complications Study.
Peeters SA, Engelen L, Buijs J, Chaturvedi N, Fuller JH, Schalkwijk CG, Stehouwer CD; EURODIAB Prospective Complications Study Group. Peeters SA, et al. Among authors: engelen l. Cardiovasc Diabetol. 2015 Mar 10;14:31. doi: 10.1186/s12933-015-0195-2. Cardiovasc Diabetol. 2015. PMID: 25848912 Free PMC article.
Low 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 levels are independently associated with macroalbuminuria, but not with retinopathy and macrovascular disease in type 1 diabetes: the EURODIAB prospective complications study.
Engelen L, Schalkwijk CG, Eussen SJ, Scheijen JL, Soedamah-Muthu SS, Chaturvedi N, Fuller JH, Stehouwer CD. Engelen L, et al. Cardiovasc Diabetol. 2015 May 30;14:67. doi: 10.1186/s12933-015-0231-2. Cardiovasc Diabetol. 2015. PMID: 26025465 Free PMC article.
Erratum to: Plasma levels of matrix metalloproteinase-2, -3, -10, and tissue inhibitor of metalloproteinase-1 are associated with vascular complications in patients with type 1 diabetes: the EURODIAB Prospective Complications Study.
Peeters SA, Engelen L, Buijs J, Chaturvedi N, Fuller JH, Schalkwijk CG, Stehouwer CD; EURODIAB Prospective Complications Study Group. Peeters SA, et al. Among authors: engelen l. Cardiovasc Diabetol. 2015 Sep 28;14:128. doi: 10.1186/s12933-015-0290-4. Cardiovasc Diabetol. 2015. PMID: 26415611 Free PMC article. No abstract available.
Circulating matrix metalloproteinases are associated with arterial stiffness in patients with type 1 diabetes: pooled analysis of three cohort studies.
Peeters SA, Engelen L, Buijs J, Chaturvedi N, Fuller JH, Jorsal A, Parving HH, Tarnow L, Theilade S, Rossing P, Schalkwijk CG, Stehouwer CDA. Peeters SA, et al. Among authors: engelen l. Cardiovasc Diabetol. 2017 Oct 25;16(1):139. doi: 10.1186/s12933-017-0620-9. Cardiovasc Diabetol. 2017. PMID: 29070037 Free PMC article.
Plasma levels of advanced glycation endproducts Nε-(carboxymethyl)lysine, Nε-(carboxyethyl)lysine, and pentosidine are not independently associated with cardiovascular disease in individuals with or without type 2 diabetes: the Hoorn and CODAM studies.
Hanssen NM, Engelen L, Ferreira I, Scheijen JL, Huijberts MS, van Greevenbroek MM, van der Kallen CJ, Dekker JM, Nijpels G, Stehouwer CD, Schalkwijk CG. Hanssen NM, et al. Among authors: engelen l. J Clin Endocrinol Metab. 2013 Aug;98(8):E1369-73. doi: 10.1210/jc.2013-1068. Epub 2013 Jun 18. J Clin Endocrinol Metab. 2013. PMID: 23780372
Irbesartan treatment does not influence plasma levels of the advanced glycation end products N(epsilon)(1-carboxymethyl)lysine and N(epsilon)(1-carboxyethyl)lysine in patients with type 2 diabetes and microalbuminuria. A randomized controlled trial.
Engelen L, Persson F, Ferreira I, Rossing P, Hovind P, Teerlink T, Stehouwer CD, Parving HH, Schalkwijk CG. Engelen L, et al. Nephrol Dial Transplant. 2011 Nov;26(11):3573-7. doi: 10.1093/ndt/gfr102. Epub 2011 Mar 8. Nephrol Dial Transplant. 2011. PMID: 21385863 Clinical Trial.
The association between the -374T/A polymorphism of the receptor for advanced glycation endproducts gene and blood pressure and arterial stiffness is modified by glucose metabolism status: the Hoorn and CoDAM studies.
Engelen L, Ferreira I, Gaens KH, Henry RM, Dekker JM, Nijpels G, Heine RJ, 't Hart LM, van Greevenbroek MM, van der Kallen CJ, Blaak EE, Feskens EJ, Ten Cate H, Stehouwer CD, Schalkwijk CG. Engelen L, et al. J Hypertens. 2010 Feb;28(2):285-93. doi: 10.1097/HJH.0b013e3283330931. J Hypertens. 2010. PMID: 20051912
Improved glycemic control induced by both metformin and repaglinide is associated with a reduction in blood levels of 3-deoxyglucosone in nonobese patients with type 2 diabetes.
Engelen L, Lund SS, Ferreira I, Tarnow L, Parving HH, Gram J, Winther K, Pedersen O, Teerlink T, Barto R, Stehouwer CD, Vaag AA, Schalkwijk CG. Engelen L, et al. Eur J Endocrinol. 2011 Mar;164(3):371-9. doi: 10.1530/EJE-10-0851. Epub 2011 Jan 4. Eur J Endocrinol. 2011. PMID: 21205874 Clinical Trial.
108 results